dinutuximab
View Patient InformationA chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.
| Synonym: | Ch 14.18UTC Ch14.18 dinutuximab beta MOAB Ch14.18 monoclonal antibody Ch14.18 |
|---|---|
| US brand name: | Unituxin |
| Foreign brand name: | Qarziba Unituxin |
| Abbreviation: | MOAB Ch14.18 |
| IND number: | 4308 5748 |
| NSC code: | 623408 |